Free tool
Rare disease stocks
We cover 8 companies grouped under the Rare disease theme. The median market value in the group is $11.23B. Across the group, the median move over the past trading day is 0.00%. Price change over the past year runs from +12.0% to +213.1% across the middle 80 percent of the group, with a median of +44.3%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
8 of 268 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return |
|---|---|---|---|---|
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $112.52B | Large cap | +40.77% |
| ARGX | argenx SE | $65.51B | Large cap | +47.90% |
| A1RG34.SA | argenx SE | $63.16B | Large cap | +36.97% |
| B1MR34.SA | BioMarin Pharmaceutical Inc. | $12.54B | Large cap | +4.97% |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $9.93B | Mid cap | +15.03% |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% |
| CPRX | Catalyst Pharmaceuticals Inc | $3.85B | Mid cap | +55.97% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.